North America was the largest region in the metabolic disorder drugs market in 2016, accounting for around 53% market share. This was mainly due to high prevalence of metabolic syndrome (combination of metabolic diseases including type-2 diabetes) in the USA. Western Europe was the second largest region accounting for around 16% market share. Asia Pacific was the third largest region accounting for around 15% market share.
Metabolic Disorder Drugs Market Global Briefing 2018 provides strategists, marketers and senior management with the critical information they need to assess the global metabolic disorder drugs sector.
Metabolic Disorder Drugs Market Global Briefing 2018 from the Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.
The market characteristics section of the report defines and explains the market.
The market size section gives the metabolic disorder drugs market revenues, covering both the historic growth of the market and forecasting the future.
Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.
Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.
The trends and strategies section highlights the likely future developments in the metabolic disorder drugs market and suggests approaches.
Reasons To Purchase
- Fully updated for 2018.
• Identify growth segments and opportunities.
• Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
• Develop strategies based on likely future developments.
• Gain a global perspective on the development of the market.
Markets Covered: Anti-diabetics drugs, Anti-thyroid drugs, and Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism).
Companies Mentioned: Sanofi S.A., Novo Nordisk A/S, AstraZeneca Plc., Johnson & Johnson, Merck & Co., Abbott Laboratories Inc., Boehringer Ingelheim GmbH, AbbVie Inc., Takeda Pharmaceuticals, Pfizer Inc., Bayer AG
Geographic scope: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Market value in $ billions.
Data segmentations: Regional breakdowns, market share of competitors, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Table of Contents
Table of Contents
Metabolic Disorder Drugs Market Characteristics 5
Metabolic Disorder Drugs Market Historic Growth (2013-17) 7
Metabolic Disorder Drugs Market Forecast Growth (2017-21) 8
Metabolic Disorder Drugs Market Segmentation 9
Global Metabolic Disorder Drugs Market, Split By Segments, 2017, $ Billion 9
Anti-diabetics Drugs 10
Anti-thyroid drugs 10
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism) 10
Global Metabolic Disorder Drugs Market, Historic and Forecast, Split By Segments, 2013-2021 11
Metabolic Disorder Drugs Market Geography Regional and Country Comparison 13
Global Metabolic Disorder Drugs Market, Split By Regions, 2017 13
Global Metabolic Disorder Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2013-2021 15
Global Metabolic Disorder Drugs Market, Split By Country, 2017 17
Global Metabolic Disorder Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2013-2021 19
Metabolic Disorder Drugs Market Competitive Landscape 21
Sanofi S.A. 22
Novo Nordisk A/S 22
AstraZeneca Plc. 22
Johnson & Johnson 22
Merck & Co. 22
Abbott Laboratories Inc. 22
Boehringer Ingelheim GmbH 22
AbbVie Inc. 22
Takeda Pharmaceticals 22
Pfizer Inc. 22
Novo Nordisk 23
AstraZeneca PLC 24
Metabolic Disorders Drugs Market Key Mergers And Acquisitions 25
Alexion Acquired Synageva 25
AstraZeneca Acquired ZS Pharma 25
Horizon Pharma Plc. Acquired Hyperion Therapeutics, Inc. 25
Horizon Pharma Plc. Acquired Raptor Pharmaceutical Corp. 25
Madrigal Pharmaceuticals Merged With Synta Pharmaceuticals Corp. 25
Metabolic Disorders Drugs Market Trends And Strategies 26
Development Of New Anti-Diabetic Drugs For Type 2 Diabetes 26
Enzyme Replacement Therapies For The Treatment Of Of Rare Metabolic Disorders 26
Increase In Mergers And Acquisitions 26
NAICS Definitions Of Industry Covered In This Report 27
Definition Of Market Covered In This Report 27
The metabolic disorders drugs market covers medications that are used in the treatment of metabolic diseases such as diabetes, thyroid, hyperparathyroidism, hypopituitarism, and hypoadrenalism. 27
Research Methodology 28
Research Inquiries 28
The Business Research Company 29
Copyright and Disclaimer 29
List of Figures
Figure 1: Global Metabolic Disorder Drugs Market, Historic Market Size, 2013-2017, $ Billion 7
Figure 2: Global Metabolic Disorder Drugs Market, Forecast Market Size, 2017 – 2021, $ Billion 8
Figure 3: Global Metabolic Disorder Drugs Market, Split By Segments, 2017, $ Billion 9
Figure 4: Global Metabolic Disorder Drugs Market, Historic and Forecast, Split By Segment, 2013 – 2021 11
Figure 5: Global Metabolic Disorder Drugs Market, Split By Region, 2017, $ Billion 13
Figure 6: Global Metabolic Disorder Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2013-2021 15
Figure 7: Global Metabolic Disorder Drugs Market, Split By Country, 2017, $ Billion 17
Figure 8: Global Metabolic Disorder Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2013-2021 19
Figure 9: Global Metabolic Disorder Drugs Market, Key Competitor Estimated Market Shares, 2017, Percentage (%) 21
The Business Research Company
47 Anchorage Point,
42 Cuba Street, Canary Wharf,
+44 207 1930 708